Philipp Schuetz1, Yannick Wirz2, Ramon Sager2, Mirjam Christ-Crain3, Daiana Stolz4, Michael Tamm4, Lila Bouadma5, Charles E Luyt6, Michel Wolff5, Jean Chastre6, Florence Tubach7, Kristina B Kristoffersen8, Olaf Burkhardt9, Tobias Welte9, Stefan Schroeder10, Vandack Nobre11, Long Wei12, Heiner C Bucher13, Djillali Annane14, Konrad Reinhart15, Ann R Falsey16, Angela Branche16, Pierre Damas17, Maarten Nijsten18, Dylan W de Lange19, Rodrigo O Deliberato20, Carolina F Oliveira21, Vera Maravić-Stojković22, Alessia Verduri23, Bianca Beghé23, Bin Cao24, Yahya Shehabi25, Jens-Ulrik S Jensen26, Caspar Corti27, Jos A H van Oers28, Albertus Beishuizen29, Armand R J Girbes30, Evelien de Jong30, Matthias Briel31, Beat Mueller32. 1. Medical University Department, Kantonsspital Aarau, Aarau, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland. Electronic address: schuetzph@gmail.com. 2. Medical University Department, Kantonsspital Aarau, Aarau, Switzerland. 3. Faculty of Medicine, University of Basel, Basel, Switzerland; Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel, Basel, Switzerland. 4. Faculty of Medicine, University of Basel, Basel, Switzerland; Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland. 5. Service de Réanimation Médicale, Université Paris 7-Denis-Diderot, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France. 6. Service de Réanimation Médicale, Université Paris 6-Pierre-et-Marie-Curie, Paris, France. 7. Département de Biostatistique, Santé publique et Information médicale, AP-HP, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. 8. Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark. 9. Department of Pulmonary Medicine, Medizinische Hochschule Hannover, Member of the German Center of Lung Research, Hannover, Germany. 10. Department of Anesthesiology and Intensive Care Medicine, Krankenhaus Dueren, Dueren, Germany. 11. Department of Intensive Care, Hospital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 12. Department of Internal and Geriatric Medicine, Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai, China. 13. Faculty of Medicine, University of Basel, Basel, Switzerland; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland. 14. Critical Care Department, Hôpital Raymond Poincaré, AP-HP, Faculty of Health Science Simone Veil, UVSQ-University Paris Saclay, Garches, France. 15. Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany. 16. Department of Medicine, University of Rochester, Rochester, NY, USA. 17. Department of General Intensive Care, University Hospital of Liege, Domaine Universitaire de Liège, Liège, Belgium. 18. University Medical Centre, University of Groningen, Groningen, Netherlands. 19. University Medical Center Utrecht and University of Utrecht, Utrecht, Netherlands. 20. Critical Care Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil. 21. Department of Internal Medicine, School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 22. Immunology Laboratory, Dedinje Cardiovascular Institute, Belgrade, Serbia. 23. Section of Respiratory Medicine, Department of Medical and Surgical Sciences, University Polyclinic of Modena, University of Modena and Reggio Emilia, Modena, Italy. 24. Center for Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China. 25. Critical Care and Peri-operative Medicine, Monash Health, Melbourne, VIC, Australia; School of Clinical Sciences, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. 26. Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases and Rheumatology, Finsencentret, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 27. Department of Respiratory Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark. 28. Elisabeth Tweesteden Hospital, Tilburg, Netherlands. 29. Medisch Spectrum Twente, Enschede, Netherlands. 30. VUmc University Medical Center, Amsterdam, Netherlands. 31. Faculty of Medicine, University of Basel, Basel, Switzerland; Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. 32. Medical University Department, Kantonsspital Aarau, Aarau, Switzerland; Faculty of Medicine, University of Basel, Basel, Switzerland.
Abstract
BACKGROUND: In February, 2017, the US Food and Drug Administration approved the blood infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory infections. This meta-analysis of patient data from 26 randomised controlled trials was designed to assess safety of procalcitonin-guided treatment in patients with acute respiratory infections from different clinical settings. METHODS: Based on a prespecified Cochrane protocol, we did a systematic literature search on the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase, and pooled individual patient data from trials in which patients with respiratory infections were randomly assigned to receive antibiotics based on procalcitonin concentrations (procalcitonin-guided group) or control. The coprimary endpoints were 30-day mortality and setting-specific treatment failure. Secondary endpoints were antibiotic use, length of stay, and antibiotic side-effects. FINDINGS: We identified 990 records from the literature search, of which 71 articles were assessed for eligibility after exclusion of 919 records. We collected data on 6708 patients from 26 eligible trials in 12 countries. Mortality at 30 days was significantly lower in procalcitonin-guided patients than in control patients (286 [9%] deaths in 3336 procalcitonin-guided patients vs 336 [10%] in 3372 controls; adjusted odds ratio [OR] 0·83 [95% CI 0·70 to 0·99], p=0·037). This mortality benefit was similar across subgroups by setting and type of infection (pinteractions>0·05), although mortality was very low in primary care and in patients with acute bronchitis. Procalcitonin guidance was also associated with a 2·4-day reduction in antibiotic exposure (5·7 vs 8·1 days [95% CI -2·71 to -2·15], p<0·0001) and a reduction in antibiotic-related side-effects (16% vs 22%, adjusted OR 0·68 [95% CI 0·57 to 0·82], p<0·0001). INTERPRETATION: Use of procalcitonin to guide antibiotic treatment in patients with acute respiratory infections reduces antibiotic exposure and side-effects, and improves survival. Widespread implementation of procalcitonin protocols in patients with acute respiratory infections thus has the potential to improve antibiotic management with positive effects on clinical outcomes and on the current threat of increasing antibiotic multiresistance. FUNDING: National Institute for Health Research.
BACKGROUND: In February, 2017, the US Food and Drug Administration approved the blood infection marker procalcitonin for guiding antibiotic therapy in patients with acute respiratory infections. This meta-analysis of patient data from 26 randomised controlled trials was designed to assess safety of procalcitonin-guided treatment in patients with acute respiratory infections from different clinical settings. METHODS: Based on a prespecified Cochrane protocol, we did a systematic literature search on the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase, and pooled individual patient data from trials in which patients with respiratory infections were randomly assigned to receive antibiotics based on procalcitonin concentrations (procalcitonin-guided group) or control. The coprimary endpoints were 30-day mortality and setting-specific treatment failure. Secondary endpoints were antibiotic use, length of stay, and antibiotic side-effects. FINDINGS: We identified 990 records from the literature search, of which 71 articles were assessed for eligibility after exclusion of 919 records. We collected data on 6708 patients from 26 eligible trials in 12 countries. Mortality at 30 days was significantly lower in procalcitonin-guided patients than in control patients (286 [9%] deaths in 3336 procalcitonin-guided patients vs 336 [10%] in 3372 controls; adjusted odds ratio [OR] 0·83 [95% CI 0·70 to 0·99], p=0·037). This mortality benefit was similar across subgroups by setting and type of infection (pinteractions>0·05), although mortality was very low in primary care and in patients with acute bronchitis. Procalcitonin guidance was also associated with a 2·4-day reduction in antibiotic exposure (5·7 vs 8·1 days [95% CI -2·71 to -2·15], p<0·0001) and a reduction in antibiotic-related side-effects (16% vs 22%, adjusted OR 0·68 [95% CI 0·57 to 0·82], p<0·0001). INTERPRETATION: Use of procalcitonin to guide antibiotic treatment in patients with acute respiratory infections reduces antibiotic exposure and side-effects, and improves survival. Widespread implementation of procalcitonin protocols in patients with acute respiratory infections thus has the potential to improve antibiotic management with positive effects on clinical outcomes and on the current threat of increasing antibiotic multiresistance. FUNDING: National Institute for Health Research.
Authors: Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier Journal: Intensive Care Med Date: 2019-01-18 Impact factor: 17.440
Authors: James M Walter; Ziyou Ren; Tyrone Yacoub; Paul A Reyfman; Raj D Shah; Hiam Abdala-Valencia; Kiwon Nam; Vince K Morgan; Kishore R Anekalla; Nikita Joshi; Alexandra C McQuattie-Pimentel; Ching-I Chen; Monica Chi; SeungHye Han; Francisco J Gonzalez-Gonzalez; Saul Soberanes; Raul P Aillon; Satoshi Watanabe; Kinola J N Williams; Ziyan Lu; Joseph Paonessa; Peter Hountras; Madonna Breganio; Nicole Borkowski; Helen K Donnelly; Jonathan P Allen; Luis A Amaral; Ankit Bharat; Alexander V Misharin; Neda Bagheri; Alan R Hauser; G R Scott Budinger; Richard G Wunderink Journal: Am J Respir Crit Care Med Date: 2019-05-15 Impact factor: 21.405